Analyzing clinical characteristics of pituitary diseases
Official title: Clinical Characteristics and Analysis of Pituitary Complex and Rare Diseases
Run by Peking Union Medical College Hospital · NCT06435195 · Data updated 2026-11-12
This study looks at the health details and treatment results of patients with rare pituitary diseases to help doctors understand these conditions better.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 3000 (estimated) |
| Sponsor | Peking Union Medical College Hospital Academic / other |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Status | Recruiting |
| Started | January 1, 2024 |
| Main results expected | September 2026 |
| Study ends | December 2026 |
| Registry record updated | May 30, 2024 |
| Trial ID | NCT06435195 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include individuals diagnosed with rare sellar diseases such as pituitary adenomas, craniopharyngiomas, and other related conditions.
✕Probably not a fit
Patients with incomplete medical records or unrelated primary central nervous system diseases may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to systematically describe the clinical characteristics and outcomes of patients with pituitary complex and rare diseases at Peking Union Medical College Hospital. Researchers will conduct detailed clinical evaluations, gather medical histories, and perform follow-up assessments to monitor disease progression and treatment outcomes. The study will compare different patient groups to identify significant differences in remission rates, comorbidities, perioperative events, and radiological findings. By leveraging a large cohort, the research seeks to enhance understanding and inform clinical practice regarding these conditions.
Why it matters
Potential benefit: If successful, this study could improve the management and prognosis of patients with pituitary complex and rare diseases.
How similar studies have gone: While similar studies have explored pituitary diseases, this comprehensive observational approach focusing on rare conditions is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosed with rare sellar diseases including but not limited to pituitary adenomas (such as Thyrotropin-secreting pituitary adenomas, GH-secreting adenomas), craniopharyngiomas, Rathke's cleft cysts, sellar region germ cell tumors, cavernous sinus syndrome, and other diseases * Detailed medical history, including clinical symptoms, treatment plans and follow-up outcomes Exclusion Criteria: * Incomplete medical records, especially missing key imaging diagnostic results * Patients with coexisting primary central nervous system diseases unrelated to sellar region diseases (such as severe traumatic brain injury) * Patients whose sellar region pathological diagnosis was changed or overturned during the follow-up period
Where it's running
-
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China Recruiting
Study contacts
- Principal investigator: Yong Yao, MD — Department of Neurosurgery, Peking Union Medical College Hospital
- Study coordinator: Yong Yao, MD
- Email: yaoyong@pumch.cn
- Phone: +8669152530
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Personalized 3D Bioprinted Colorectal Cancer Microenvironment Model
This study tests patient-derived, 3D-bioprinted cancer models that include tumor, fibroblast, and immune cells to see if they can better predict how colorectal cancer will respond to treatment.
-
Glycogen Storage Disease and Brain Function in People Like You
This study tests whether people with glycogen storage disease perform differently on cognitive tests and show different brain imaging features compared with healthy peers.
-
FAPI PET Imaging to See Fibroblast Activity in Nonischemic Cardiomyopathy
This study tests whether a special PET/CT scan using 18F-AlF-NOTA-FAPI-04 can reveal active fibroblast activity in the hearts of adults with nonischemic cardiomyopathy to help understand disease behavior and guide care.
-
Ivonescimab with GEMOX as neoadjuvant and conversion therapy for biliary tract cancer
This study tests whether adding Ivonescimab to GEMOX can help patients with biliary tract cancer shrink tumors before surgery or enable conversion to operable disease.
-
Sacituzumab Tirumotecan plus Pembrolizumab in advanced biliary tract cancer
This study tests whether the combination of Sacituzumab Tirumotecan and Pembrolizumab can help people with advanced biliary tract cancer who have already had at least one approved therapy fail.
-
Lenvatinib plus chemotherapy for pancreatic neuroendocrine tumors with liver metastases
This study tests whether adding lenvatinib to chemotherapy helps people with pancreatic neuroendocrine tumors that have spread to the liver, after first-line therapy has stopped working.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.